Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Rossoni · SciRah

Researcher profile · Semantic Scholar

G. Rossoni

Share profile

G. Rossoni — researcher profile on SciRah

h-index: 6
Works: 38
Citations: 387

Most-cited papers

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc, P. Zucali, A. Santoro, G. Ceresoli +15 more
2010Journal of Clinical Oncology109 citations Open access
Semantic Scholar
Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example
A. Corti, F. Curnis, G. Rossoni, F. Marcucci +1 more
2013BioDrugs70 citations Open access
Semantic Scholar
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
V. Gregorc, G. Citterio, G. Vitali, A. Spreafico +14 more
2010European Journal of Cancer56 citations
Semantic Scholar
Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
V. Gregorc, F. D. de Braud, T. De Pas, R. Scalamogna +13 more
2011Clinical Cancer Research51 citations
Semantic Scholar
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz, R. Talamini, G. Rossoni, A. Santo +9 more
2012BMC Research Notes49 citations Open access
Semantic Scholar
Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
P. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi +12 more
2011British Journal of Cancer19 citations Open access
Semantic Scholar
Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC).
M. Viganó, R. Cavina, S. Novello, F. Grossi +10 more
2011Journal of Clinical Oncology6 citations
Semantic Scholar
NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) .
V. Gregorc, A. Bulotta, M. Viganó, G. Citterio +10 more
2011Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT).
A. Bulotta, V. Gregorc, G. Rossoni, G. Todisco +5 more
20133 citations
Semantic Scholar
Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example
A. Corti, F. Curnis, G. Rossoni, F. Marcucci +1 more
2013BioDrugs3 citations Open access
Semantic Scholar
Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors
V. Gregorc, F. D. de Braud, T. De Pas, R. Scalamogna +14 more
20113 citations
Semantic Scholar
Treatment-free interval (TFI) after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): Findings from the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC.
V. Gregorc, D. Ghio, C. Sallemi, A. Bulotta +7 more
20152 citations
Semantic Scholar
Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC).
V. Gregorc, N. Zilembo, F. Grossi, T. De Pas +6 more
20132 citations
Semantic Scholar
NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM).
G. Rossoni, V. Gregorc, M. Viganó, A. Bulotta +3 more
20122 citations
Semantic Scholar
Ochrobactrum anthropi: a rare case of endocarditis
Francesca Salvotti, G. Rossoni, M. Pilia, Pietro Carleo +5 more
2024Italian Journal of Medicine1 citations Open access
Semantic Scholar
Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).
V. Gregorc, A. Bulotta, M. Viganó, G. Citterio +10 more
20161 citations
Semantic Scholar
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz, R. Talamini, G. Rossoni, A. Santo +9 more
2012BMC Research Notes1 citations Open access
Semantic Scholar
9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results
V. Gregore, N. Zilembo, F. Grossi, G. Rossoni +6 more
20111 citations
Semantic Scholar
Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results.
V. Gregorc, N. Zilembo, F. Grossi, G. Rossoni +10 more
2011Journal of Clinical Oncology1 citations
Semantic Scholar
A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)
G. Citterio, A. Santoro, R. Scalamogna, T. Pressiani +6 more
20081 citations
Semantic Scholar
Safety and antitumour activity of NGR-hTNF, a selective vascular targeting agent (VTA), administered at low dose in pre-treated patients with hepatocellular carcinoma (HCC): preliminary results of a phase II trial
G. Citterio, A. Santoro, T. Pressiani, R. Scalamogna +5 more
20081 citations
Semantic Scholar
Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015.
V. Gregorc, M. Viganó, A. Bulotta, G. Citterio +10 more
20160 citations
Semantic Scholar
Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously treated patients with malignant pleural mesothelioma (MPM) enrolled in the NGR015 phase 3 trial.
A. Bulotta, V. Gregorc, M. Viganó, G. Rossoni +5 more
20150 citations
Semantic Scholar
Relationships between occurrence of chills and clinical outcome during NGR-hTNF therapy.
A. Bulotta, V. Gregorc, G. Rossoni, M. Viganó +3 more
20140 citations
Semantic Scholar
Impact of treatment-free interval (TFI) and disease control rate (DCR) on survival outcome in relapsed malignant pleural mesothelioma (MPM).
V. Gregorc, A. Bulotta, M. Viganó, D. Ghio +7 more
20140 citations
Semantic Scholar
Infusion-related reactions (IRR) during NGR-hTNF therapy as potential predictors of clinical outcome.
G. Rossoni, V. Gregorc, A. Bulotta, M. Viganó +3 more
20130 citations
Semantic Scholar
Treatment-free interval (TFI) after first-line therapy (FLT) and disease control rate (DCR) on second-line therapy (SLT): Impact on overall survival (OS) in relapsed malignant pleural mesothelioma (MPM).
M. Viganó, V. Gregorc, D. Ghio, A. Bulotta +6 more
20130 citations
Semantic Scholar
Association Between Peripheral Blood Lymphocyte Count (PBLC) and Outcome in Patients with Solid Tumors Treated with Ngr-Htnf
A. Bulotta, V. Gregorc, G. Rossoni, G. Todisco +3 more
20120 citations Open access
Semantic Scholar
Front-Line Chemotherapy with or without NGR-HTNF in Non-Small Cell Lung Cancer (NSCLC)
V. Gregorc, N. Zilembo, F. Grossi, T. De Pas +6 more
20120 citations Open access
Semantic Scholar
Correlation of Infusion-Related Reactions (IRR) and Outcome in Patients Receiving Ngr-Htnf Treatment
G. Rossoni, V. Gregorc, A. Bulotta, M. Viganó +3 more
20120 citations Open access
Semantic Scholar
NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC).
V. Gregorc, N. Zilembo, F. Grossi, T. De Pas +7 more
20120 citations
Semantic Scholar
Background and Methods Background and methods Results Randomized phase II trial of NGR-hTNF and chemotherapy in chemo-naïve patients with non-small cell lung cancer (NSCLC): preliminary results
V. Gregorc, N. Zilembo, F. Grossi, G. Rossoni +6 more
20110 citations
Semantic Scholar
9103 POSTER Phase II Trial of NGR-hTNF and Doxorubicin in Relapsed Small Cell Lung Cancer (SCLC)
M. Viganó, R. Cavina, S. Novello, F. Grossi +6 more
20110 citations
Semantic Scholar
Predictive potential of angiogenic plasma biomarkers (PBs) in phase I trial with NGR-hTNF.
G. Rossoni, V. Gregorc, G. Citterio, A. Spreafico +6 more
20100 citations
Semantic Scholar
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC).
A. Santoro, G. Citterio, T. Pressiani, F. D. de Braud +6 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient
M. Giovannini, V. Gregorc, M. Viganó, E. Roca +9 more
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Gregorc×32
Invite
V. Gregorc — researcher profile on SciRah
A. Lambiase×30
Invite
A. Lambiase — researcher profile on SciRah
C. Bordignon×26
Invite
C. Bordignon — researcher profile on SciRah
G. Citterio×16
Invite
G. Citterio — researcher profile on SciRah

×16

Invite

M. Viganó — researcher profile on SciRah

Invite

A. Bulotta — researcher profile on SciRah

Scialini Colombi×9

Invite

Scialini Colombi — researcher profile on SciRah

F. Caligaris-cappio×8

Invite

F. Caligaris-cappio — researcher profile on SciRah

Invite

G. Donadoni — researcher profile on SciRah

Invite

F. Grossi — researcher profile on SciRah

Invite

N. Zilembo — researcher profile on SciRah

Invite

T. De Pas — researcher profile on SciRah